Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy

A. B. Weitberg, S. A. Weitzman, E. Watkins, C. Hinkle, S. O'Rourke, J. L. Dienstag

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

We evaluated the immunogenicity and safety of three 40 μg doses of hepatitis B vaccine in oncology patients receiving chemotherapy. Of 76 patients screened for entry into the study, 13 (17%) already had been exposed to hepatitis B and were ineligible; 26 chose to join the study. The cumulative life-table response rate during the 12-month observation period was 70.8%; adequate immune response was linked to survival, 73% in survivors completing the study and 9% in nonsurvivors. Adverse effects were minor. We conclude that hepatitis B vaccine is safe and usually effective in inducing immunity in oncology patients younger than 60 years of age who are receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)718-722
Number of pages5
JournalJournal of Clinical Oncology
Volume3
Issue number5
DOIs
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy'. Together they form a unique fingerprint.

Cite this